For Immediate Release
Chicago, IL – January 11, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Morgan Stanley (MS - Free Report) , Intuitive Surgical, Inc. (ISRG - Free Report) , Colgate-Palmolive Company (CL - Free Report) , Keurig Dr Pepper (KDP - Free Report) and Prudential Financial (PRU - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Morgan Stanley, Intuitive Surgical and Colgate-Palmolive
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, Morgan Stanley, Intuitive Surgical, Inc. and Colgate-Palmolive Company. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Morgan Stanley’s shares have lost 12.6% in the last six months, outperforming the Zacks Investment Banking industry, which has lost 16.2% over the same period. The company possesses an impressive earnings surprise history, beating the Zacks Consensus Estimate in each of the trailing four quarters.
The company’s efforts to strengthen wealth management business, focus on corporate lending, steady loan growth, higher interest rates and normalized levels of trading activities will further support revenues. Also, its steady capital deployment plan reflects strong balance sheet position.
However, a slowdown in debt originations will hamper underwriting fee income growth. Further, mounting operating expenses is a major near-term concern for the company.
Shares of Buy-ranked Intuitive Surgical have gained +2.6% in the last six months, outperforming the Zacks Medical Instruments industry which has lost -4.9% over the same period. The company’s robotic platform – da Vinci System – recorded solid growth in recent times. This is led by strong performance in U.S. general surgery procedures and global urologic procedures. Management expects strong contributions from da Vinci in 2019 as well. Commencement of da Vinci sale in Taiwan also adds to the positives.
Management is also optimistic about the company’s collaboration with InTouch Health. On the negative side, the company expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption.
Shares of Colgate-Palmolive have underperformed the Zacks Consumer Staples industry over the past three months (-1.7% vs. +8.1%). Colgate is smoothly progressing with its cost-savings program. Notably, the Global Growth and Efficiency Program and Funding the Growth initiative are delivering impressive results.
Management approved an expansion and extension of the program through Dec 31, 2019, which will enable it to take advantage of the incremental opportunities while streamlining operations. Further, the company’s meet or beat earnings long track record remains impressive.
It also provided a favorable earnings view for 2018. However, the stock has lagged the industry in the past three months. It has a dismal sales trend, missing estimates in 21 of the last 22 quarters. Management anticipates a tough backdrop due to uncertain global markets and slowing category growth worldwide.
Other noteworthy reports we are featuring today include Keurig Dr Pepper and Prudential Financial.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.